ClinicalTrials.gg
Not yet recruitingNCT07912294Updated Nov 3, 2026

Comparing Calcium Hydroxylapatite and Hyaluronic Acid for Interdental Papilla Reconstruction

An interventional study of Calcium Hydroxylapatite (CaHA) Injectable Filler. and Hyaluronic Acid (HA) Injectable Filler in Loss of Interdental Papillae and Black Triangles Syndrome (BTS), sponsored by King Abdulaziz University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by King Abdulaziz University · Not applicable, Interventional, and Treatment

Updated Nov 3, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to compare two injectable materials, calcium hydroxylapatite (Radiesse®) and hyaluronic acid, for treating gaps between the teeth caused by loss of gum tissue. These gaps, commonly known as "black triangles," can affect the appearance of a person's smile and may cause food to become trapped between the teeth.

Hyaluronic acid has been used to improve the appearance of these gaps, but its effects may not last for a long time. Calcium hydroxylapatite is another injectable material that may help the body produce collagen, a natural protein that supports gum tissue. This study will investigate whether calcium hydroxylapatite can provide better or longer-lasting results compared with hyaluronic acid.

The study will take place at the Faculty of Dentistry, King Abdulaziz University, Jeddah, Saudi Arabia. Approximately 20 healthy adults who have two similar gaps between their front teeth will be invited to participate.

Each participant will receive both treatments. One gap will be treated with diluted calcium hydroxylapatite, while the other will be treated with hyaluronic acid. The treatment for each site will be selected randomly to ensure a fair comparison. Each site will receive one injection.

Participants will be examined before treatment and again after 3 weeks, 3 months, and 6 months to assess the results.

During these visits, photographs and clinical measurements will be taken to evaluate changes in the size of the gaps and the amount of gum tissue between the teeth. Participants will also be asked about their satisfaction with the appearance of their gums, any discomfort experienced during treatment, and whether they have noticed an improvement in their smile. Any side effects or complications will also be recorded.

The researchers will compare how well the two materials improve the appearance of the gaps and how long the improvements last.

Participation will be voluntary, and all participants will receive information about the study before signing a consent form. Their personal information will be kept confidential, and they may withdraw from the study at any time without affecting their dental care.

The main goal of this study is to identify whether diluted calcium hydroxylapatite or hyaluronic acid provides better and longer-lasting improvement in the appearance of gaps between the teeth. The findings may help dentists choose more effective, minimally invasive treatments for patients with missing gum tissue between their teeth.

02

Conditions studied

  • Loss of Interdental Papillae
  • Black Triangles Syndrome (BTS)

Keywords

  • Interdental papilla
  • Black triangle
  • open gingival embrasure
  • hyaluronic acid
  • Radiesse
  • Calcium hydroxylapatite
03

In context

Lead sponsor

King Abdulaziz University is the lead sponsor of 98 studies on the registry; 19 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older.
  • Systemically healthy individuals with no history of chronic systemic diseases.
  • Patients with a healthy periodontium.
  • Patients presenting with two comparable interdental papilla deficiencies in the esthetic zone.
  • Patients with Class I interdental papilla loss according to the Nordland and Tarnow classification.

Exclusion criteria

Exclusion Criteria:

  • Patients with chronic systemic diseases.
  • Pregnant or lactating women.
  • Current smokers.
  • Children and adolescents under 18 years of age.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Hyper-Diluted Calcium Hydroxylapatite (Radiesse®)

    Interdental papilla deficiencies assigned to this treatment will receive a single injection of hyper-diluted calcium hydroxylapatite (Radiesse®), prepared at a 1:2 dilution ratio using saline and lidocaine. The intervention aims to improve interdental papillary fill and stimulate collagen production, potentially providing longer-lasting tissue improvement. Clinical outcomes will be evaluated at baseline, 3 weeks, 3 months, and 6 months following treatment.

    Device: Calcium Hydroxylapatite (CaHA) Injectable Filler.

  • Active comparator
    Hyaluronic Acid (HA)

    Interdental papilla deficiencies assigned to this treatment will receive a single injection of hyaluronic acid (HA). The intervention aims to improve interdental papillary fill by increasing soft tissue volume and reducing the appearance of black triangles. Clinical outcomes will be evaluated at baseline, 3 weeks, 3 months, and 6 months following treatment.

    Device: Hyaluronic Acid (HA) Injectable Filler

Interventions

  • DeviceCalcium Hydroxylapatite (CaHA) Injectable Filler.

    Hyper-diluted calcium hydroxylapatite (Radiesse®) will be used for the treatment of Class I interdental papilla deficiencies. The material will be prepared at a 1:2 dilution ratio using saline and lidocaine, mixed through a Luer-lock syringe connection. Each randomly assigned interdental site will receive a single injection. The treatment aims to stimulate collagen production, improve interdental papillary fill, and enhance soft tissue volume and stability. Clinical outcomes will be evaluated at baseline, 3 weeks, 3 months, and 6 months after treatment. Hyaluronic acid (HA) injectable filler will be used for the treatment of Class I interdental papilla deficiencies. Each randomly assigned interdental site will receive a single injection of HA to increase soft tissue volume, improve interdental papillary fill, and reduce the appearance of black triangles. Clinical outcomes will be evaluated at baseline, 3 weeks, 3 months, and 6 months after treatment.

  • DeviceHyaluronic Acid (HA) Injectable Filler

    Hyaluronic acid (HA) injectable filler will be used for the treatment of Class I interdental papilla deficiencies. Each randomly assigned interdental site will receive a single injection of HA to increase soft tissue volume, improve interdental papillary fill, and reduce the appearance of black triangles. Clinical outcomes will be evaluated at baseline, 3 weeks, 3 months, and 6 months after treatment.

06

What researchers measure

Primary outcomes

  1. Reduction in Black Triangle Area

    Change in the area of the open gingival embrasure (black triangle) following treatment, measured in square millimeters (mm²) using standardized calibrated digital clinical photographs. The reduction in black triangle area will be compared between the calcium hydroxylapatite and hyaluronic acid treatment sites to evaluate the effectiveness of papillary reconstruction.

    Time frame: Baseline, 3 weeks, 3 months, and 6 months after treatment.

  2. Change in Interdental Papilla Height

    Change in interdental papilla height (mm) from baseline following treatment with hyper-diluted calcium hydroxylapatite or hyaluronic acid. Papillary height will be measured using standardized digital clinical photographs calibrated with a UNC-15 periodontal probe and analyzed using image-analysis software (ImageJ). The distance from the papilla tip to a reference line connecting the adjacent gingival margins will be measured. Changes in papillary height will be compared between the two treatment sites.

    Time frame: Baseline, 3 weeks, 3 months, and 6 months after treatment.

Secondary outcomes

  1. Change in Interdental Papilla Thickness

    Change in interdental papilla thickness (mm) following treatment with calcium hydroxylapatite or hyaluronic acid. Tissue thickness will be assessed using a calibrated endodontic file fitted with a silicone stopper at a standardized reference point. Changes in tissue thickness will be compared between treatment sites to estimate improvements in papillary tissue bulk.

    Time frame: Baseline, 3 weeks, 3 months, and 6 months after treatment.

  2. Patient Satisfaction With Esthetic Outcomes

    Patient satisfaction with the appearance of the treated interdental papilla will be assessed using a Visual Analog Scale (VAS). Participants will evaluate their satisfaction with the esthetic improvement achieved following each treatment. Satisfaction scores will be compared between the two treatment sites.

    Time frame: 3 weeks, 3 months, and 6 months after treatment.

  3. Global Aesthetic Improvement Scale (GAIS)

    Esthetic improvement will be assessed using the Global Aesthetic Improvement Scale (GAIS), a five-point scale ranging from "worse" to "very much improved." Both participants and investigators will evaluate the improvement in interdental papilla appearance compared with baseline. Scores will be compared between the two treatment sites.

    Time frame: 3 weeks, 3 months, and 6 months after treatment.

  4. Stability of Interdental Papillary Fill

    The stability of interdental papillary reconstruction will be evaluated by comparing changes in papilla height and black triangle dimensions across follow-up visits. The maintenance of treatment-related improvements at 6 months will be assessed to compare the durability of calcium hydroxylapatite and hyaluronic acid injections.

    Time frame: 3 weeks, 3 months, and 6 months after treatment.

Other outcomes

  1. Patient Satisfaction Questionnaire (PSQ-18)

    Patient-reported satisfaction will be evaluated using the Patient Satisfaction Questionnaire Short Form (PSQ-18), consisting of 18 items. The questionnaire will assess satisfaction with treatment, comfort, perceived improvement, and overall treatment experience. Responses will be compared between the two treatment sites.

    Time frame: 3 weeks, 3 months, and 6 months after treatment.

  2. Adverse Events and Complications

    Any adverse effects or complications associated with calcium hydroxylapatite or hyaluronic acid injections will be recorded and compared between the treatment sites. The number and nature of reported complications will be documented to evaluate the safety of both interventions.

    Time frame: From the injection procedure through the 6-month follow-up period.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Jul 2028, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2026
First posted
Nov 3, 2026
StartEst.
Nov 2026
Primary completionEst.
Jul 2028
CompletionEst.
Sep 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07912294
Lead sponsor
King Abdulaziz University
Responsible party
Rusha Alyafi (DDS, MS, King Abdulaziz University) — Principal investigator
First posted
Nov 3, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jul 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Nov 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion